65671-54-7

Basic information

• Product Name: (S)-2-[(tert-Butoxycarbonyl)amino]-5-(dimethylamino)pentanoic acid
• Synonyms: (S)-2-[(tert-Butoxycarbonyl)amino]-5-(dimethylamino)pentanoic acid
• CAS NO: 65671-54-7
• Molecular Formula: C₁₂H₂₄N₂O₄
• Molecular Weight: 260.32996
• Mol File: 65671-54-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 400.3±40.0 °C(Predicted)
• Appearance: /
• Density: 1.079±0.06 g/cm3(Predicted)
• PKA: 3.82±0.21(Predicted)
• CAS DataBase Reference: (S)-2-[(tert-Butoxycarbonyl)amino]-5-(dimethylamino)pentanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-[(tert-Butoxycarbonyl)amino]-5-(dimethylamino)pentanoic acid(65671-54-7)
• EPA Substance Registry System: (S)-2-[(tert-Butoxycarbonyl)amino]-5-(dimethylamino)pentanoic acid(65671-54-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 22-26-36/37/39
• Hazardous Substances Data: 65671-54-7(Hazardous Substances Data)

Usage

General Description

(S)-2-[(tert-butoxycarbonyl)amino]-5-(dimethylamino)pentanoic acid, commonly known as Boc-Dap(DMAP), is a chemical compound used in the field of biochemistry and organic synthesis. It is a derivative of amino acid pentanoic acid, with a tert-butoxycarbonyl (Boc) protecting group attached to the amino group. (S)-2-[(tert-butoxycarbonyl)amino]-5-(dimethylamino)pentanoic acid has potential use in the development of peptide-based pharmaceuticals and drug delivery systems due to its ability to protect and control the reactivity of amino acids during synthesis. Boc-Dap(DMAP) is also used in the synthesis of complex peptides and peptidomimetic molecules, as well as in the study of protein structure and function. Additionally, it has been investigated for its potential applications in the development of antimicrobial and anticancer agents.

Upstream product

• 50-00-0 formaldehyd 
• 21887-64-9 N₂-(tert-butoxycarbonyl)-L-ornithine 
• 2480-93-5 Boc-Orn(Z)-OH 

Downstream Products

• 884049-27-8 [4-tert-butoxycarbonylamino-5-(4-{4-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-tetrahydro-pyran-4-carbonyl}-piperazin-1-yl)-5-oxo-pentyl]-trimethyl-ammonium 

Relevant articles and documents

TGR5 AGONISTS

TGR5 agonists of structural formula VIII(Q), wherein X, R1, R2, and R5 are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

Design and synthesis of novel sulfonamide-containing bradykinin hB 2 receptor antagonists. 2. Synthesis and structure-activity relationships of α,α-cycloalkylglycine sulfonamides

Recently we reported on the design and synthesis of a novel class of selective nonpeptide bradykinin (BK) B2 receptor antagonists (J. Med. Chem. 2006, 3602-3613). This work led to the discovery of MEN 15442, an antagonist with subnanomolar affinity for the human B2 receptor (hB2R), which also displayed significant and prolonged activity in vivo (for up to 210 min) against BK-induced bronchoconstriction in the guinea-pig at a dose of 300 nmol/kg (it), while demonstrating only a slight effect on BK-induced hypotension. Here we describe the further optimization of this series of compounds aimed at maximizing the effect on bronchoconstriction and minimizing the effect on hypotension, with a view to developing topically delivered drugs for airway diseases. The work led to the discovery of MEN 16132, a compound which, after intratracheal or aerosol administration, inhibited, in a dose-dependent manner, BK-induced bronchoconstricton in the airways, while showing minimal systemic activity. This compound was selected as a preclinical candidate for the topical treatment of airway diseases involving kinin B2 receptor stimulation.